89bio, Inc. (ETNB)
| Previous close | 16.27 |
| Open | 16.18 |
| Bid | 16.60 x 900 |
| Ask | 16.62 x 1100 |
| Day's range | 15.91 - 16.87 |
| 52-week range | 2.00 - 18.03 |
| Volume | |
| Avg. volume | 1,969,805 |
| Market cap | 875.907M |
| Beta (5Y monthly) | 0.75 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.84 |
| Earnings date | 09 May 2023 - 15 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 34.63 |
- Motley Fool
Why Shares of 89bio Soared This Week
Shares of clinical-stage biopharmaceutical company 89bio (NASDAQ: ETNB) were up 36.2% for the week as of Friday morning, according to data provided by S&P Global Market Intelligence. The healthcare company, which focuses on therapies to treat liver and cardio-metabolic diseases, released positive news regarding its lead therapy, pegozafermin. In a phase 2b study, a weekly 44-milligram dose and a weekly 30-mg dose of the drug both met the primary endpoints in treating patients with nonalcoholic steatohepatitis (NASH), a disease that causes the liver to swell and be damaged.
- GlobeNewswire
89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock
SAN FRANCISCO, March 24, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of its previously announced underwritten public offering of 16,923,077 shares of its common stock at a public offering price per share of $16.25. In addition, 89bio has granted the underwriters of the offering
- GlobeNewswire
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, March 22, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stoc
